Immune Design is a clinical stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design’s clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM.
Events & Presentations
Nov 14, 2018 4:40 AM EST
Jefferies 2018 London Healthcare Conference
Nov 06, 2018 4:30 PM EST
Immune Design Third Quarter 2018 Financial Results
Phone Replay will be available around 4.30pm PT on November 6 through 4.30pm PT on November 13.
(855) 859-2056 or (404) 537-3406
Conference ID: 1359112